Furazolidone Quadruple Regimen Eradicate H. Pylori Infection
NCT06823791 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 493
Last updated 2025-02-12
Summary
Research protocol:
Experimental group:
First line solution (furazolidone regimen): esomeprazole magnesium 20 mg +colloidal bismuth pectin 200mg+ amoxicillin 1000 mg + furazolidone 100 mg, twice daily, for 14 days.
Patients who is still positive for H. pylori infection after the first line solution select the second line solution (high-dose dual regimen): esomeprazole magnesium 20 mg and amoxicillin 750 mg, 4 times daily, for 14 days.
Control group:
First line solution (clarithromycin regimen): esomeprazole magnesium 20 mg +colloidal bismuth pectin 200mg+ amoxicillin 1000 mg + clarithromycin 500 mg, twice a day, for 14 days.
Patients who is still positive for H. pylori infection after the first line solution select the second line solution (high-dose dual regimen): esomeprazole magnesium 20 mg and amoxicillin 750 mg, 4 times daily, for 14 days.
Main study endpoint:
The difference in the eradication rate of H. pylori infection between the furazolidone quadruple regimen and the clarithromycin quadruple regimen.
Secondary study endpoint:
1. Safety and compliance of the furazolidone quadruple regimen.
2. Comparison of high-dose dual therapy with furazolidone quadruple therapy and clarithromycin quadruple therapy on H. pylori eradication rate.
3. 1-year recurrence and recurrence rate of H. pylori infection.
Conditions
- Helicobacter Pylori Infection
- Eradication
Interventions
- DRUG
-
Furazolidone
esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + furazolidone 100 mg bid, for 14 days. After stopping the medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months and 12 months, the experiment stop. If H. pylori is positive, check again after 6 months. If H. pylori is still positive, high-dose dual therapy will be used to resist H. pylori again. After stopping the second medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months, and the experiment stops. If H. pylori is still positive, check again after 6 months, and the experiment stops.
- DRUG
-
Clarithromycin
esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + clarithromycin 500 mg bid, for 14 days. After stopping the medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months and 12 months, the experiment stop. If H. pylori is positive, check again after 6 months. If H. pylori is still positive, high-dose dual therapy will be used to resist H. pylori again. After stopping the second medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months, and the experiment stops. If H. pylori is still positive, check again after 6 months, and the experiment stops.
Sponsors & Collaborators
-
Liaocheng People's Hospital
lead OTHER
Principal Investigators
-
Lifeng Liu · Liaocheng Peoples hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-08-01
- Primary Completion
- 2024-07-30
- Completion
- 2024-07-30
Countries
- China
Study Locations
More Related Trials
-
Empirical Rescue Therapies of Helicobacter Pylori Infection
NCT01668927 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection
NCT03658733 ·Status: UNKNOWN ·Phase: PHASE4
-
Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection
NCT00520949 ·Status: COMPLETED ·Phase: NA
-
Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT04678492 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study
NCT06731023 ·Status: NOT_YET_RECRUITING
-
Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.
NCT03571230 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori
NCT01667575 ·Status: COMPLETED ·Phase: PHASE4
-
The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
NCT04810793 ·Status: COMPLETED
-
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
NCT05049902 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection
NCT04991584 ·Status: UNKNOWN ·Phase: NA
-
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
NCT05742568 ·Status: COMPLETED ·Phase: PHASE4
-
Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection
NCT03616405 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin
NCT06351891 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection
NCT03658746 ·Status: COMPLETED ·Phase: PHASE4
-
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days
NCT04901117 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection
NCT05126121 ·Status: UNKNOWN ·Phase: NA
-
The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
NCT05173493 ·Status: COMPLETED
-
Helicobacter Pylori Eradication and Follow-up
NCT05061732 ·Status: RECRUITING ·Phase: PHASE4
-
High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection
NCT06561698 ·Status: RECRUITING ·Phase: PHASE4
-
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
NCT04558502 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication
NCT02827942 ·Status: COMPLETED ·Phase: PHASE3
-
Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.
NCT04090021 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection
NCT03726099 ·Status: UNKNOWN ·Phase: PHASE4
-
Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients
NCT05023577 ·Status: UNKNOWN ·Phase: PHASE4
-
The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection
NCT02359331 ·Status: TERMINATED ·Phase: NA